TACT908
TACT908, also known as dimethylamine, is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches. It is a positional isomer of the tryptamine serotonergic psychedelic N,''N-dimethyltryptamine in which the indole ring has been replaced with an indolizine ring.
The drug acts as a serotonin 5-HT1B and 5-HT2A receptor agonist. Its at the serotonin 5-HT2A receptor is 52nM and its at the serotonin 5-HT1B receptor is 143nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT2A receptor agonist. It showed little or no activity at 45other screened targets, including the serotonin 5-HT1A, 5-HT2B, and 5-HT3 receptors as well as the monoamine transporters. Other serotonin receptors besides the preceding, such as the serotonin 5-HT2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor, specifically of monoamine oxidase A .
TACT908 is under development by Tactogen. It was patented by Matthew Baggott of Tactogen in 2023. As of January 2025, the drug is in preclinical research for cluster headaches.
The α-methyl and N''-desmethyl analogue of TACT908, 1ZP2MA propan-2-yl]amine or 1-, has also been characterized and described. It is the indolizine analogue of α,N-dimethyltryptamine. 1ZP2MA was found to be a potent dopamine releasing agent, with an of 62nM.